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REVIEW
Fifteen years of irinotecan therapy 
for pediatric sarcoma: where to next?
Lars M. Wagner* 
Abstract 
Over the past 15 years, irinotecan has emerged as an important agent for treating pediatric sarcoma patients. This 
review summarizes the activity noted in previous studies, and outlines current issues regarding scheduling, route of 
administration, and amelioration of side effects. Also discussed are new pegylated and nanoliposomal formulations 
of irinotecan and its active metabolite, SN-38, as well as future plans for how irinotecan may be used in combination 
with other conventional cytotoxic as well as targeted agents.
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Background
Irinotecan is a camptothecin analogue that has taken on 
growing importance in the treatment of pediatric sar-
comas such as Ewing sarcoma and rhabdomyosarcoma. 
Irinotecan is a prodrug that is spontaneously converted 
by endogenous carboxylesterases to its active metabo-
lite, SN-38. Like other camptothecins such as topotecan, 
SN-38 mediates cytotoxicity by stabilizing the DNA-
topoisomerase I complex created during replication. This 
stabilization prevents religation of DNA, and so “poi-
sons” the activity of the topoisomerase I enzyme.
Irinotecan was initially approved by the US Food and 
Drug Administration for the treatment of colon cancer 
in 1996. Three years later, Furman et  al. reported the 
first pediatric phase I clinical trial of irinotecan [1]. This 
landmark study was based on the preclinical observation 
of improved efficacy when using a protracted multi-day 
schedule, as opposed to a single dose given every 3 weeks 
[2]. Such protracted scheduling provides greater expo-
sure of this S phase-specific drug, especially when given 
for 5 consecutive days 2 weeks in a row (d × 5 × 2 sched-
ule). The objective responses observed in three patients 
with relapsed rhabdomyosarcoma were consistent with 
the enhanced preclinical activity seen in pediatric sar-
coma xenografts using this schedule, and this trial was 
followed by subsequent studies designed to: (1) explore 
various schedules of administration, (2) reduce toxicity, 
(3) improve convenience and maximize SN-38 exposures, 
and (4) define the activity of irinotecan as a single agent 
and in combination with other drugs. In this review, we 
will identify key findings from these past studies, and 
also discuss new formulations and potentially synergistic 
therapeutic partners for irinotecan.
Schedules of irinotecan administration
Several schedules of irinotecan administration have 
been studied in children, ranging from one large dose 
every 3 weeks as used in adults [3, 4], to once weekly [5], 
daily ×  3 [6], daily ×  5 [7], and the original d ×  5 ×  2 
schedule first studied by Furman et al. [1, 8, 9]. All sched-
ules have been tolerable, although notably the pattern of 
toxicity is schedule-dependent. For example, when using 
larger but infrequent dosages, the principal toxicity is 
myelosuppression. In contrast, diarrhea and abdominal 
pain are more prominent with the protracted lower-dose 
schedule.
Only one pediatric study has directly compared the 
efficacy of different schedules of irinotecan. In that trial, 
89 evaluable patients with recurrent rhabdomyosar-
coma were randomized to receive vincristine combined 
with irinotecan given either on a d ×  5 or a d ×  5 ×  2 
schedule [10]. The overall incidence of grade 3–4 adverse 
events was similar. As expected, patients on the shorter 
schedule experienced more myelosuppression, while 
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those on the longer schedule had more gastrointestinal 
toxicity. Importantly, because there was no significant 
difference in efficacy, and since the shorter schedule is 
more convenient and less expensive, the d × 5 schedule 
has emerged as the most popular schedule for newer 
regimens.
Ameliorating toxicity
In most pediatric studies of irinotecan, myelosuppres-
sion is mild and growth factor is rarely required. Instead, 
diarrhea and abdominal pain are the usual dose-limit-
ing toxicities. Early-onset diarrhea may occur during or 
immediately after irinotecan administration, and is usu-
ally manageable with atropine. More common and prob-
lematic is the late-onset diarrhea noted about 1  week 
after starting therapy. While prompt administration of 
loperamide may help with mild gastrointestinal toxicity, 
some patients experience severe diarrhea and abdomi-
nal pain, and this morbidity can impact compliance even 
when the tumor is responding to treatment [7, 8].
The mechanism of late-onset diarrhea is complex. 
Local accumulation of the active metabolite SN-38 in 
the gut results in direct cytotoxicity and secretory diar-
rhea [11]. SN-38 is usually inactivated through hepatic 
glucuronidation and then excreted in the bile into the 
intestine. However, reactivation of SN-38 can occur as a 
result of glucuronidases which are produced by enteric 
bacteria [reviewed in 12]. Therefore, one approach for 
reducing irinotecan-associated diarrhea is to use antibi-
otics to eradicate the Gram negative aerobic bacteria that 
produce these glucuronidases, thereby reducing the reac-
tivation of local SN-38 in the gut. That strategy proved 
efficacious in a phase I trial of orally administered iri-
notecan in which the daily use of the oral cephalosporin 
cefixime reduced the incidence of grade 3–4 diarrhea 
such that the maximum tolerated dose was 50 % higher 
than what could be achieved without antibiotic support 
[13]. A 50 % increase in the tolerable dose was also noted 
in patients receiving intravenous irinotecan in a similar 
trial [14]. This practice of using cephalosporins before, 
during, and after the irinotecan course has now been uni-
versally employed in all pediatric trials of orally admin-
istered irinotecan, given that the poor bioavailability 
requires higher drug doses to achieve acceptable SN-38 
exposures. One common approach when using the d × 5 
schedule of irinotecan is to administer cephalosporins 
(either cefixime or cefpodoxime) starting 2  days before 
chemotherapy and continuing until 3 days after finishing 
chemotherapy, which makes for a 10-day course of antibi-
otics and avoids the continuous administration that may 
lead to antibiotic resistance or C difficile infections. In 
contrast to orally administered irinotecan, cephalosporin 
prophylaxis is not routinely done when standard doses 
of irinotecan are given intravenously, as the incidence of 
≥grade 3 diarrhea is under 10  % [7]. Instead, antibiotic 
prophylaxis is usually only used in patients experiencing 
significant toxicity during the previous course, as a way 
to maintain dose intensity [15].
The detoxification of SN-38 through hepatic glu-
curonidaiton is mediated by UGT1A1. In adult stud-
ies, patients with the UGT1A1*28 polymorphism have 
increased toxicity from irinotecan [16]. However, in 
pediatric studies this genotype/phenotype relationship 
has not been observed. For example, in the largest series 
of 74 patients taken from 5 pediatric studies in patients 
receiving protracted irinotecan, there was no increase in 
either hematologic or gastrointestinal toxicity in patients 
homozygous for UGT1A1*28 [17]. Based on this and 
similar reports [18], prospective genotyping of pediatric 
patients receiving protracted irinotecan is not routinely 
performed.
Maximizing convenience: oral administration
The protracted administration schedule of intravenous 
irinotecan is inconvenient for patients and costly to 
administer, prompting interest in oral administration. 
There is no commercially available tablet or capsule for-
mulation of irinotecan, and so the intravenous prepara-
tion has been given orally. Because of the bitter taste, 
it is usually masked in cran-grape juice to improve pal-
atability [13]. The oral bioavailability is less than 20  %, 
requiring higher dose of oral irinotecan are necessary to 
achieve SN-38 exposures similar to intravenous adminis-
tration. However, metabolism of orally administered iri-
notecan is more efficient, given that the intestinal tract 
contains high levels of carboxylesterases, which may pre-
systemically metabolize irinotecan to SN-38 and increase 
the SN-38/irinotecan ratio by threefold or more [19].
Pediatric clinical trials have shown the dose of 60 mg/
m2/dose on a d × 5 × 2 schedule was tolerable and pro-
duced SN-38 exposures that were similar to those seen 
with intravenous doses of 20  mg/m2, when accounting 
for the wide intrapatient variability in irinotecan metabo-
lism [13, 18]. However, the relationship between oral and 
intravenous dosing is not exactly linear. For example, the 
daily oral dose of 90  mg/m2 appears comparable to the 
intravenous dose of 50 mg/m2 when using similar phar-
macokinetic assays [20]. To date there have been over 200 
pediatric patients treated on trials of oral irinotecan [13, 
18, 20–22]. Although there have been no studies directly 
comparing the efficacy of oral vs. intravenous adminis-
tration, the roughly similar SN-38 exposures, response 
rates, and toxicity profiles suggest they are fairly equiva-
lent when using the dose conversions noted above.
The benefits of oral administration include greater 
patient convenience and time away from the clinic, as 
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well as up to five-fold reduction in cost [23]. The strat-
egy is generally feasible, and because of the considerable 
benefits could be considered in most situations. However, 
there are occasional patients who have difficulty taking 
the medication orally, no matter what methods are used 
to mask the flavor. Also, for patients with ongoing nausea 
or chronic gastrointestinal complaints, oral absorption 
may be limited and make this strategy inappropriate.
Improving SN‑38 exposure
Efforts to increase SN-38 exposure are based on the 
assumption of a dose–response relationship for irinote-
can therapy for pediatric sarcoma, which is intuitive but 
not yet proven clinically. Given gastrointestinal toxicity is 
the usual limiting toxicity, one strategy for dose escalation 
is to reduce irinotecan-associated diarrhea with cefix-
ime as described above. McGreggor et  al. have shown 
in a phase I trial this approach allows for an increase in 
intravenous irinotecan dosing from 20 to 30 mg/m2/day 
on the d × 5 × 2 schedule [14], although the efficacy of 
higher doses has not been formally assessed.
Another strategy to increase drug exposure is to reduce 
efflux of irinotecan out of cells by using the small mol-
ecule gefitinib to inhibit the ABCG2 drug transporter. 
Through this mechanism gefitinib can reverse irinotecan 
resistance in  vitro even in cell lines that lack amplifica-
tion of the epidermal growth factor receptor [24], which 
is the usual therapeutic target for this agent. ABCG2 is 
expressed in the small intestine, and co-administration 
of gefitinib can increase the bioavailability of oral irinote-
can by four-fold [25]. Dose-finding studies of gefitinib in 
combination with both intravenous and oral irinotecan 
have been reported [22, 25], but there has not yet been 
efficacy assessment in a phase II trial.
Activity of single‑agent irinotecan
Single-agent irinotecan has been studied in a variety 
of pediatric trials. As predicted from mouse xenograft 
models [2, 26], responses have consistently been seen 
in patients with rhabdomyosarcoma and Ewing sar-
coma. Response rates as high as 38 % for Ewing sarcoma/
primitive neuroectodermal tumor and 16 % for rhabdo-
myosarcoma have been reported [9]. However, activity 
of single-agent irinotecan in larger multi-institutional 
phase II studies has been disappointing. For example, 
in a Children’s Oncology Group (COG) phase II trial 
using intravenous administration on a d ×  5 schedule, 
response rates in relapsed patients were under 10 % for 
both rhabdomyosarcoma and Ewing sarcoma [7]. These 
results have led to the current practice of partnering 
irinotecan with another agent, such as vincristine or 
temozolomide, as described below. There is less experi-
ence using irinotecan for treatment of osteosarcoma or 
non-rhabdomyosarcoma soft tissue sarcoma, with only 
rare responses noted [20, 27].
Identifying potential therapeutic partners
Preclinical experience shows camptothecins can syn-
ergize with microtubule inhibitors such as vincristine 
[28]. This combination has been most thoroughly evalu-
ated in rhabdomyosarcoma, a disease in which vincris-
tine is an established active agent. In newly-diagnosed 
patients with metastatic rhabdomyosarcoma, Pappo 
et al. reported a response rate of 42 % with single-agent 
irinotecan, which increased to 70  % when combined 
with vincristine [15]. The vincristine +  irinotecan (VI) 
combination is tolerable, and a recent phase III trial for 
newly-diagnosed intermediate-risk rhabdomyosarcoma 
showed that incorporating cassettes of VI alternating 
with vincristine, dactinomycin, and cyclophosphamide 
(VAC) is as effective as using VAC alone, which had his-
torically been the standard treatment for these patients 
[29]. As expected, febrile neutropenia and thrombocy-
topenia were less in patients receiving the VI cassettes, 
although there was more diarrhea. Moving forward, the 
COG is planning to use the VAC + VI regimen because 
it reduces the overall exposure to alkylating agents that 
may cause secondary malignancies and infertility.
Irinotecan has also been paired with the methylat-
ing agent temozolomide, given that modest myelosup-
pression seen from irinotecan allows for combination 
with drugs having more hematologic toxicity. Houghton 
et  al. demonstrated schedule-dependent synergy with 
these two drugs against rhabdomyosarcoma xenografts 
[30], with maximum activity seen when temozolomide 
is given at least 1  h before irinotecan [31]. This is con-
sistent with the proposed mechanism in which temozo-
lomide-induced methylation of DNA causes localization 
of topoisomerase I-DNA complexes that are more sus-
ceptible to the cytotoxic effects of irinotecan [32]. This 
temozolomide +  irinotecan (TI) combination has been 
particularly active in Ewing sarcoma, with reported 
response rates between 29 and 63 % [33–35]. The dose-
limiting toxicities of irinotecan (diarrhea) and temozo-
lomide (myelosuppression) are non-overlapping, and 
the combination is well-suited for oral administration. 
Because of the tolerability of this regimen, investigators 
have used TI as a backbone on which to add other drugs 
such as vincristine [20, 36, 37], as well as biologic agents 
discussed below.
A variety of other conventional chemotherapy agents 
have been combined with irinotecan to treat pediat-
ric sarcoma, including carboplatin [38], oxaliplatin and/
or gemcitabine [39–41], ifosfamide [42], and docetaxel 
[43]. None have achieved the response rates reported 
with VI or TI, and in some cases unexpected toxicities 
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or pharmacokinetic interactions were seen. For example, 
although intermittent dosing of oxaliplatin and irinote-
can was well tolerated in adults with colon cancer, severe 
pancreatic inflammation was seen when oxaliplatin was 
used together with protracted irinotecan in children [39]. 
Further, in a combination trial of ifosfamide and irinote-
can for osteosarcoma patients, markedly reduced con-
centrations of SN-38 were noted, suggesting a major drug 
interaction that could compromise efficacy [42]. These 
findings demonstrate the importance of performing 
dose-finding and pharmacokinetic studies for novel com-
binations. A summary of published combination phase II 
and III studies of irinotecan-based regimens for pediatric 
sarcoma is provided in Table 1.
Future combinations to be explored
One focus in sarcoma therapeutics has been the addi-
tion of targeted agents onto conventional chemotherapy 
backbones. This strategy is particularly attractive if the 
targeted agent has either single-agent activity, or if it 
potentiates the cytotoxicity of standard chemotherapy 
drugs. An example is the addition of mTOR inhibitors 
such as temsirolimus to the TI regimen [21]. Responses 
in rhabdomyosarcoma patients to single-agent temsiroli-
mus have been limited [44], but its combination with 
cyclophosphamide and vinorelbine showed promis-
ing activity in a recent COG trial [45]. Results from this 
study provided the rationale for the next upcoming COG 
phase III trial for intermediate-risk rhabdomyosarcoma, 
which will study the VAC/VI backbone with or without 
temsirolimus.
Another example is the combination of irinotecan-
based regimens with a monoclonal antibody against the 
insulin growth factor receptor type I receptor (IGF-1R). 
Although the single-agent response rates to IGF-1R anti-
bodies in phase II trials have been generally disappoint-
ing [reviewed in 46], there have been occasional patients 
with impressive and durable responses in patients with 
Ewing sarcoma and rhabdomyosarcoma [47, 48]. The 
COG has recently completed a phase II trial of the IGF-
1R antibody cixutumumab together with multi-agent 
conventional chemotherapy for patients with newly-diag-
nosed metastatic rhabdomyosarcoma (ClinicalTrials.gov 
identifier NCT01055314). Interestingly, in the compara-
tor arm of the study temozolomide was added on to the 
same chemotherapy backbone, which included irinote-
can. Final results of this study are not yet available.
A third example is the use of inhibitors against the 
DNA repair protein poly(ADP-ribose) polymerase 
(PARP). This class of drugs was identified through a func-
tional genomics approach and found to have marked 
preclinical in  vitro and in  vivo activity against Ewing 
sarcoma [49]. Although efficacy as monotherapy may be 
limited [50], the combination of a PARP inhibitor with 
temozolomide is now being explored in multiple trials, 
due to the potentiated effects of PARP inhibition follow-
ing temozolomide-mediated DNA damage [51]. Stewart 
et al. have recently reported that further preclinical ben-
efit may be seen by combining PARP inhibitors with both 
temozolomide and irinotecan [52].
Other molecular approaches include the targeting of 
Wee1, which helps regulate the response to DNA damage 
Table 1 Key phase II and III studies using irinotecan in pediatric sarcoma patients
RMS rhabdomyosarcoma, ES Ewing sarcoma
Reference Lead author Phase Other agents given with 
irinotecan
Population Comments
[30] Hawkins III Vincristine Newly-diagnosed  
intermediate-risk RMS
VI alternating with VAC is as efficacious as VAC 
alone, and may reduce long-term toxicity
[15] Pappo II Vincristine Newly-diagnosed metastatic RMS Response rate to induction rose from 46–70 % 
after addition of vincristine
[38] Dharmajan II Carboplatin, radiation Newly-diagnosed intermediate  
or high-risk RMS
Local control rate of 89 %; reduced mucositis 
compared to historical controls
[10] Mascarenhas II Vincristine Relapsed RMS Similar rates of response and grade 3–4 toxicity 
between d × 5 vs d × 5 × 2 schedule
[37] Mixon II Temozolomide, vincristine Relapsed RMS One complete response in 4 patients
[33] Kurucu II Temozolomide Relapsed ES Response rate 55 %
[34] Wagner II Temozolomide Relapsed ES Response rate 29 %
[35] Casey II Temozolomide Relapsed ES Response rate 63 %
[36] Raciborska II Temozolomide, vincristine Relapsed ES Response rate 68 %
[43] Yoon II Docetaxel Relapsed ES Response rate 33 %
[42] Crews II Ifosfamide Newly-diagnosed high-risk  
osteosarcoma
Ifosfamide reduced SN-38 exposures
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by inhibiting CDK1. Wee1 can be targeted with the small 
molecule MK-1775, which showed in  vitro activity 
against a variety of sarcoma cell lines [53]. Combination 
with oral irinotecan is now being explored in a COG 
Phase I trial (ClinicalTrials.gov identifier NCT02095132), 
based on preclinical synergy with of this combination in 
neuroblastoma models [54].
It is important to note that not all irinotecan combina-
tions may show benefit for sarcoma, even if used com-
monly for other tumor types. Although widely employed 
to treat high-grade glioma, the combination of irinotecan 
and the anti-VEGF antibody bevacizumab has shown no 
evidence to date of compelling activity in sarcoma in the 
limited studies to date [55, 56].
New formulations of irinotecan and SN‑38
The process of pegylation joins a drug with a multim-
eric polyethylene glycol using a glycine linker in order to 
prolong exposure to the agent. This approach has been 
applied in an effort to prolong the exposure to irinote-
can and/or SN-38. These approaches are attractive in that 
preclinical studies have demonstrated responses even in 
irinotecan-resistant xenografts [57], and the schedule of 
administration is less frequent and therefore more con-
venient for patients. In a dose-finding study of pegylated 
SN-38 (EZN-2208), a maximum tolerated dose of 24 mg/
m2 once every 3 weeks was identified, which was higher 
than the adult MTD of 16.5  mg/m2 [58]. Some gastro-
intestinal toxicity was seen at lower doses, with myelo-
suppression being dose-limiting at the higher doses. 
Unfortunately, no responses were seen in the 12 sarcoma 
patients treated on this phase I trial.
The pegylated irinotecan compound etirinotecan 
(NKTR-102) has shown promising activity in phase II 
studies of breast and ovarian cancer using a once every 
3 weeks schedule [59, 60], and is moving forward in phase 
III trials. With this formulation, dehydration and diarrhea 
were the most common grade 3–4 toxicities, occurring in 
just over 20 % of patients. No trials have yet been reported 
which partner either of these drugs with other agents, and 
the long-term future of these agents likely awaits a review 
of their benefits in larger upcoming trials.
Liposomal preparations of irinotecan have also been 
developed, and may preferentially accumulate in tumor 
cells through enhanced permeability and retention [61]. 
Nanoliposomal irinotecan (MM-398) also minimizes 
exposure of drug in the serum and so stabilizes the active 
lactone form of irinotecan versus the inactive carboxylate 
form [62]. This drug has superior activity over compa-
rably dosed conventional irinotecan in mouse models of 
Ewing sarcoma [63], and is currently being evaluated in 
a pediatric clinical trial together with cyclophosphamide 
(ClinicalTrials.gov identifier NCT02013336).
Conclusions
The role of irinotecan in combination with other agents is 
becoming more established for the treatment of rhabdo-
myosarcoma, as well as for relapsed Ewing sarcoma. The 
d ×  5 schedule may be as effective as more protracted 
administration, and is being used for many current and 
planned irinotecan trials. Oral administration is feasi-
ble for the majority of patients, may have similar activ-
ity and toxicity, and offers reduced cost and time away 
from the clinic. For these reasons, oral administration 
using a 5-day schedule is now commonly employed in 
the relapse setting at our institution, as well as in several 
ongoing clinical trials. Prophylaxis with cephalosporins is 
an important way to reduce severe irinotecan-associated 
diarrhea, and is necessary for all patients receiving oral 
administration of irinotecan. At present there is not a 
reliable way to identify patients at greatest risk of toxic-
ity, and antibiotic prophylaxis is not routinely necessary 
for patients receiving intravenous irinotecan at standard 
doses. The single-agent activity of irinotecan is limited, 
although its toxicity profile allows for ready combination 
with a variety of other chemotherapy drugs, especially 
vincristine and temozolomide. Particularly exciting is the 
potential for combining irinotecan-based backbones with 
newer targeted therapies, and the opportunities for test-
ing of the new longer-acting preparations either alone or 
in combination with other drugs.
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